Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GuARD trial of GR1014 cutaneous gel for prevention of radiodermatitis during adjuvant breast radiotherapy
2023-508728-36-00Phase 2Completed
- Sponsor
- Graegis Pharmaceuticals
- Start
- May 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in radiodermatitis comparing GR1014 cutaneous gel with Placebo / vehicle gel (2 arms). Primary endpoint: No radiation dermatitis during treatment period. Started May 2024; status: completed.
02
Drugs
GR1014
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on 2023-508728-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508728-36-00.